Latest stories on INCY
Incyte Shares Retreat After Best Day In A Year Despite Opzelura EU Nod
Stocktwits News42 · neutralproduct/pr
Guggenheim raises Incyte stock price target to $150 on strong results
Investing.com Analyst Ratings61 · neutralanalyst
H.C. Wainwright raises Incyte stock price target to $150 on revenue beat
Investing.com Analyst Ratings61 · neutralanalyst
Incyte Corporation 2026 Q2 - Results - Earnings Call Presentation
Seeking Alpha50 · neutralearnings
Oppenheimer raises Incyte stock price target to $120 on revenue beat
Investing.com Analyst Ratings61 · neutralanalyst
Incyte forecasts $5.130B-$5.260B 2026 net sales as Opzelura guidance rises to $1.050B-$1.1B after CMS settlement
Seeking Alpha67 · bullishearnings
Incyte Corporation (INCY) Q2 2026 Earnings Call Transcript
Seeking Alpha50 · neutralearnings
Incyte Q2 Earnings Call Highlights
Yahoo Finance73 · bullishearnings
Incyte: From Buy To Hold After A 93% Rally (Rating Downgrade)
Seeking Alpha46 · neutralanalyst
Incyte Tops Second-Quarter Expectations but Shares Slip on Lower Revenue Outlook
InvestorsHub48 · neutralearnings
Incyte raises sales outlook as Opzelura, cancer portfolio fuel strong quarter
Seeking Alpha73 · bullishearnings
Incyte lifts annual revenue forecast after settlement with CMS
Reuters63 · neutralgeneral
Incyte Non-GAAP EPS of $3.09 beats by $0.94, revenue of $1.67B beats by $180M
Seeking Alpha73 · bullishearnings
INCYTE CORP (INCY) files 8-K
SEC 8-K50 · neutralgeneral
Incyte Reports Second Quarter 2026 Financial Results and Provides Business Updates | INCY Stock News
StockTitan56 · neutralearnings
Final Trades: Meta, ServiceNow, eBay and Incyte
CNBC57 · neutralanalyst
Final Trades: Meta, ServiceNow, eBay and Incyte
CNBC50 · neutralgeneral
Incyte Q2 2026 Earnings Preview
Seeking Alpha56 · neutralearnings
H.C. Wainwright reiterates Incyte stock rating on Halozyme deal
Investing.com Analyst Ratings56 · neutralanalyst
Halozyme Signs ENHANZE Collaboration with Incyte for Subcutaneous INCA033989 Development
Yahoo Finance63 · neutralm&a
Halozyme in deal with Incyte to use Enhanze technology for neoplasms candidate
Seeking Alpha63 · neutralm&a
Incyte: Profitable Biotech That Could Be Close To Exploding
Seeking Alpha73 · bullishanalyst